FT Options’s iShares Biotechnology ETF IBB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q3
$86K Buy
88,500
+19,500
+28% +$2.08M 0.13% 107
2017
Q2
$165K Buy
69,000
+3,000
+5% +$295K 0.28% 63
2017
Q1
$101K Buy
+66,000
New +$6.32M 0.13% 114
2016
Q4
Sell
-45,000
Closed -$221K 306
2016
Q3
$221K Buy
+45,000
New +$4.28M 0.18% 99
2016
Q2
Sell
-120,000
Closed -$19K 377
2016
Q1
$19K Buy
+120,000
New +$10.7M 0.02% 213

Other funds holding IBB

FT Options's IBB Position: Q3 2017 in Review

FT Options reduced its iShares Biotechnology ETF (IBB) stake by 46% in Q3 2017, selling an estimated $989K and leaving 10,986 shares worth $1.22M. The position accounts for 1.84% of the portfolio, ranked #17.

FT Options first reported a position in IBB in Q3 2016 and has held it in 4 quarters since. The position peaked at $2.09M in Q2 2017. 583 funds tracked by Wall St. Rank hold IBB as of Q3 2017.

  • FT Options held 10,986 shares of iShares Biotechnology ETF worth $1.22M as of Q3 2017.
  • FT Options sold 9,255 iShares Biotechnology ETF shares in Q3 2017, an estimated $989K.
  • iShares Biotechnology ETF made up 1.84% of FT Options's portfolio in Q3 2017, its #17 holding.
  • FT Options first reported a position in iShares Biotechnology ETF in Q3 2016 and has held it in 4 quarters since.
  • FT Options's iShares Biotechnology ETF position peaked at $2.09M in Q2 2017.
  • 583 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2017.

Based on FT Options's 13F filing for Q3 2017, filed 13 Nov 2017.